NCT03358823

Brief Summary

The aims of study on Angelman syndrome:

  1. 1.Establish the Angelman syndrome database
  2. 2.Explore the brain Network of Angelman Syndrome Based on Multi-modal Brain Image and Neural-EEG Data

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 20, 2017

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

November 25, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 2, 2017

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 20, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 20, 2019

Completed
Last Updated

April 26, 2021

Status Verified

April 1, 2021

Enrollment Period

2 years

First QC Date

November 25, 2017

Last Update Submit

April 23, 2021

Conditions

Keywords

AS databaseMRIEEG

Outcome Measures

Primary Outcomes (1)

  • Angelman syndrome databas; Brain Network of Angelman syndrome

    1. Analysis of geneal situation of Chinese Angelman syndrome including phenotype ,genotype, brain image ,EEG data, living quality ,comorbidy evolulation(n=200) 2. Study on the Brain Network of Angelman Syndrome Based on Multi-modal Brain Image and Neural-EEG Data

    0-18 years old

Study Arms (1)

Angelman syndrome

Cases were children with the diagnosis meet the all 4 major criteria developmental delay, speech impairment, movement or balance disorder, and behavioral characteristics, as well as the presence of 3 of 6 minor criteria, including postnatal deceleration of head growth, seizures, abnormal EEG, sleep disturbance, attraction to or fascination with water, and drooling (summary by Tan et al., 2011). all patients meet the 4 known genetic mechanisms can cause Angelman syndrome (AS).,including maternal deletions involving chromosome 15q11.2-q13;paternal uniparental disomy of 15q11.2-q13;imprinting defectsand mutations in the gene encoding the ubiquitin-protein ligase E3A gene (UBE3A; 601623)

Eligibility Criteria

AgeUp to 18 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodProbability Sample
Study Population

The patients of Angelman syndrome meet the clinical and genetic diagnosis criteria

You may qualify if:

  • Clinical and molecular diagnosis of Angelman syndrome.
  • Agreed and completed the MRI scan and EEG-recording by using oral chloral hydrate.

You may not qualify if:

  • Reject MRI scan and EEG-recording by using oral chloral hydrate or unable to complete the scan.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Children's Hospital of Fudan University

Shanghai, Shanghai Municipality, 200232, China

Location

Related Publications (2)

  • Aghakhanyan G, Bonanni P, Randazzo G, Nappi S, Tessarotto F, De Martin L, Frijia F, De Marchi D, De Masi F, Kuppers B, Lombardo F, Caramella D, Montanaro D. From Cortical and Subcortical Grey Matter Abnormalities to Neurobehavioral Phenotype of Angelman Syndrome: A Voxel-Based Morphometry Study. PLoS One. 2016 Sep 14;11(9):e0162817. doi: 10.1371/journal.pone.0162817. eCollection 2016.

    PMID: 27626634BACKGROUND
  • Tiwari VN, Jeong JW, Wilson BJ, Behen ME, Chugani HT, Sundaram SK. Relationship between aberrant brain connectivity and clinical features in Angelman Syndrome: a new method using tract based spatial statistics of DTI color-coded orientation maps. Neuroimage. 2012 Jan 2;59(1):349-55. doi: 10.1016/j.neuroimage.2011.07.067. Epub 2011 Jul 30.

Biospecimen

Retention: SAMPLES WITH DNA

whole blood 2\*5ml, (isolate Plasma, Serum and white cell)

MeSH Terms

Conditions

Angelman Syndrome

Condition Hierarchy (Ancestors)

Movement DisordersCentral Nervous System DiseasesNervous System DiseasesAbnormalities, MultipleCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesChromosome DisordersGenetic Diseases, InbornImprinting Disorders

Study Officials

  • Yi Wang, Dr.

    Children's Hospital of Fudan University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Target Duration
2 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Vice Prsident Chlidren's Hospital of Fudan University

Study Record Dates

First Submitted

November 25, 2017

First Posted

December 2, 2017

Study Start

May 20, 2017

Primary Completion

May 20, 2019

Study Completion

May 20, 2019

Last Updated

April 26, 2021

Record last verified: 2021-04

Data Sharing

IPD Sharing
Will not share

Locations